Author

R. Cagan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 2 Approach:deep learning· 2 Organism:Drosophila· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

B. Cong· 2 shared E. Stamou· 2 shared A. C. Tan· 1 shared A. H. Uribe· 1 shared A. Matly· 1 shared A. Schlessinger· 1 shared A. Tropsha· 1 shared C. Hecht· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Cong

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Flow zoometry of Drosophila

W. Peterson, J. Arenson, S. Hata, L. Kacenauskaite, T. Kobayashi, T. Otsuka, H. Wang, Y. Wada, K. Hiramatsu, Z. He, J.-E. Clement, C. Zhang, C. Hu, P. McCann, H. Kanazawa, , K. Goda

This paper introduces flow zoometry, a high-throughput screening method for Drosophila, enabling rapid, automated, and high-resolution analysis of whole animals.

bioRxiv · Apr 4, 2024 · PreprintBioengineering

WNT Signalling Promotes NF-κB Activation and Drug Resistance in KRAS-Mutant Colorectal Cancer

B. Cong, E. Stamou, K. Pennel, M. McKenzie, A. Matly, J. Edwards, R. Cagan

This study shows that WNT signaling enhances NF-κB activation and drug resistance in KRAS-mutant colorectal cancer, suggesting a therapeutic strategy targeting WNT and MEK pathways.

bioRxiv · Dec 21, 2023Cancer Biology

Colon Cancer Cells Evade Drug Action by Enhancing Drug Metabolism

B. Cong, T. Thakur, A. H. Uribe, E. Stamou, S. Gopinath, O. Maddocks, R. Cagan

The paper identifies glucuronidation pathway upregulation as a mechanism by which colon cancer cells develop resistance to trametinib, showing that inhibiting this pathway can reverse resistance in both Drosophila and mouse models.

bioRxiv · Dec 21, 2023Cancer Biology

Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: the Multi-Targeting Drug DREAM Challenge

Z. Xiong, M. Jeon, R. J. Allaway, J. Kang, D. Park, J. Lee, H. Jeon, M. Ko, H. Jiang, M. Zheng, A. C. Tan, X. Guo, The Multi-Targeting Drug DREAM Challenge Community, K. K. Dang, A. Tropsha, , R. Cagan

The paper reports on a DREAM Challenge to predict multi-target kinase inhibitors for RET-based tumors and Tauopathy, using neural network-based machine learning approaches.

bioRxiv · Feb 15, 2021Pharmacology & Toxicology